Journal of the Korean Association of Oral and Maxillofacial Surgeons

  • 제35권5호
  • /
  • Pages.353-360
  • /
  • 2009
  • /
  • 2234-7550(pISSN)
  • /
  • 2234-5930(eISSN)
대한구강악안면외과학회 (The Korean Association of Oral and Maxillofacial Surgeons)
권호 표지

비스포스포네이트로 인한 하악 및 상악골에 발생한 골괴사에 대한 임상적 연구

CLINICAL STUDY OF BISPHOSPHONATE-INDUCED OSTEONECROSIS OF MANDIBULAR AND MAXILLARY BONE

  • 정혜린 (아주대학교 의과대학 치과학교실) ;
  • 김태완 (아주대학교 의과대학 치과학교실) ;
  • 이정근 (아주대학교 의과대학 치과학교실) ;
  • 송승일 (아주대학교 의과대학 치과학교실)
  • Joeng, Hye-Rin (Department of Dentistry, School of Medicine, Ajou University) ;
  • Kim, Tae-Wan (Department of Dentistry, School of Medicine, Ajou University) ;
  • Lee, Jeong-Keun (Department of Dentistry, School of Medicine, Ajou University) ;
  • Song, Seung-Il (Department of Dentistry, School of Medicine, Ajou University)
  • 발행 : 2009.10.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Bisphosphonates are compounds widely used in the treatment of various metabolic and malignant bone disease. Recently, an association between bisphosphonate use and a rare dental condition termed 'osteonecrosis of the jaw(ONJ)' has been reported. Bisphosphonate-related osteonecrosis of the jaw(BRONJ) is rare, but serious, side effect of bisphosphonate therapy in affected patients. It is characterized by poor wound healing and spontaneous intra-oral soft tissue break down, which lead to exposure of necrotic maxillary and mandibular bone. We reviewed 11 patients of BRONJ visited Ajou University Hospital Dental clinic from May 2007 to November 2008. The management of the patients included cessation of bisphosphonate therapy and various surgical restorative procedures and conservative care there after. Aggressive debridement is contraindicated. A new complication of bisphosphonate therapy administration, osteonecrosis of jaws, seems to be developing. The improved results after cessation of the medication should make clinicians reconsider the merits of the rampant use of bisphosphonates, while further investigation is needed to completely elucidate this complication.

키워드

참고문헌

  1. Marx RE. Pamidronate (AREDIA) and zoledronate(ZOMETA) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115 -8 https://doi.org/10.1016/S0278-2391(03)00720-1
  2. Saad F, Lipton A. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease. Semin Oncol 2007;34(Suppl 4):S17-S23 https://doi.org/10.1053/j.seminoncol.2007.10.006
  3. Owens G, Jackson R, Lewiecki EM. An integrated approach:bisphosphonate management for the treatment of osteoporosis. Am J Manag Care 2007;13 Suppl 11): S290-S308
  4. Diel IJ, Bergner R, Grotz KA. Adverse effects of bisphophonates: current issues. J Support Oncol 2007;5:475-82
  5. Migliorati CA, Casiglia J, Epstein J. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J AM Dent Assoc 2005;136:1658-68
  6. Woo SB, Hellstein JW, Kalmar JR. Systematic review:bisphosphonate and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61 https://doi.org/10.7326/0003-4819-144-10-200605160-00009
  7. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-76 https://doi.org/10.1016/j.joms.2006.11.003
  8. Khosla S, Burr D, Cauley J. Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91 https://doi.org/10.1359/jbmr.0707onj
  9. Berenson JR, Hillner BE, Kyle RA, American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. Clin Oncol 2002;20:3719-36 https://doi.org/10.1200/JCO.2002.06.037
  10. Ruggiero SL, Mehrotra B, Rosenberg TJ. Osteonecrosis of the jaws associated with the use of bisphosphonates : a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527-34 https://doi.org/10.1016/j.joms.2004.02.004
  11. Marx RE, Sawatari Y, Fortin M. BroumanV.Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg. 2005;63:1567-75 https://doi.org/10.1016/j.joms.2005.07.010
  12. Papapoulos SE. Bisphosphonate actions: physical chemistry revisited. Bone 2006;38:613-6 https://doi.org/10.1016/j.bone.2006.01.141
  13. Zavras AI, Zhu S. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis? J Oral Maxillofac Surg 2006;64:917-23 https://doi.org/10.1016/j.joms.2006.02.011
  14. Rogers MJ, Gordon S, Benford HL. Cellular and molecular mechanism of action of bisphosphonates. Cancer 2000: 88(Suppl): 2961-78
  15. Yarom N, Yahalom R, Shoshani Y. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 2007;18:1363-70 https://doi.org/10.1007/s00198-007-0384-2
  16. Marx RE. Oral & intravenous bisphosphonate-induced osteonecrosis of the jaws: History, etiology, prevention, and treatment. 1st ed. Chicago: Quintessence Publishing, 2007
  17. Lam DK, Sandor GK, Holmes HI. A review of bisphos phonate - associated osteonecrosis of the jaws and its management. J Can Dent Assoc 2007;73: 417-22
  18. Reid IR. Bolland MJ. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 2007;41:318-20 https://doi.org/10.1016/j.bone.2007.04.196
  19. Phal PM, Myall RW, Assael LA. Imaging findings of bisphoshonate-associated osteonecrosis of the jaws. Am J Neuroradiol 2007;28:1139-45 https://doi.org/10.3174/ajnr.A0518
  20. Kwon YD, Yoon BW, Walter C. Bisphosphonate, is it an emerging risk factor in oral surgery? J Kor Maxillofac Plastic Recon Surg 2007;29:456-62
  21. Wilkinson G, Kuo YF, Freeman KJ. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: A population-based analysis. J Natl Cancer Inst 2007;99:1016-24 https://doi.org/10.1093/jnci/djm025
  22. Mavrokokki A, Cheng A, Stein B. Nature and frequency of bisphosphonate -associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-23 https://doi.org/10.1016/j.joms.2006.10.061
  23. Drexler HC, Risaw W, Konerding MA.: Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J 2000;20:4319-23
  24. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonate. Med 2005;353:99-102 https://doi.org/10.1056/NEJM200507073530120
  25. Guerrero ME, Jacobs R, Loubele M. State-of-the-art on cone beam CT imaging for preoperative planning of implant placement. Clin Oral Investig 2006;10:1-7 https://doi.org/10.1007/s00784-005-0031-2
  26. Schulze D, Blessmann M, Pohlenz P. Diagnostic criteria for the detection of mandibular osteomyelitis using cone-beam computed tomography. Dentomaxillofac Radiol 2006;35:232-5 https://doi.org/10.1259/dmfr/71331738
  27. Wutzl A, Eisenmenger G, Hoffmann M. Osteonecrosis of the jaws and bisphosphonate treatmentin cancer patients. Wien Klin Wochenschr 2006;118:473-8 https://doi.org/10.1007/s00508-006-0644-8
  28. Rizzoli R, Pierre D, Burlet NS. Review: Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 2008;42: 841-7 https://doi.org/10.1016/j.bone.2008.01.003
  29. Chhoeu AH, Siegel D. Landesberg R, Althoff M. A case series of hyperbaric oxygen treatment for non-radiation induced osteonecrosis of the jaw. J Oral MaxillofacSurg. 2006;64(Sup):80-1 https://doi.org/10.1016/j.joms.2006.06.149